OBJECTIVE: To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder. METHODS: Data were pooled from five, 4-6-week acute studies. PANSS Total, Positive, Negative, and General Psychopathology Subscale improvements were analyzed, as well as all 30 individual PANSS items. RESULTS:Aripiprazole had statistically significant decreases versus placebo on PANSS subscales at Week 4, similar to those seen with haloperidol. Aripiprazole-treated patients also showed significant decreases versus placebo in 26 of the 30 PANSS items (all p<0.05). CONCLUSION:Aripiprazole demonstrates statistically and clinically significant efficacy across a range of symptoms in schizophrenia.
RCT Entities:
OBJECTIVE: To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder. METHODS: Data were pooled from five, 4-6-week acute studies. PANSS Total, Positive, Negative, and General Psychopathology Subscale improvements were analyzed, as well as all 30 individual PANSS items. RESULTS:Aripiprazole had statistically significant decreases versus placebo on PANSS subscales at Week 4, similar to those seen with haloperidol. Aripiprazole-treated patients also showed significant decreases versus placebo in 26 of the 30 PANSS items (all p<0.05). CONCLUSION:Aripiprazole demonstrates statistically and clinically significant efficacy across a range of symptoms in schizophrenia.
Authors: Lei Chen; Joseph A Johnston; Bruce J Kinon; Virginia Stauffer; Paul Succop; Tiago R Marques; Haya Ascher-Svanum Journal: BMC Psychiatry Date: 2013-11-28 Impact factor: 3.630